Table 1.
Preparation of DDM and DDM/rhBMP-2
| Study/reference | DDM source | Subjects | Feature of carrier | Demineralization | rhBMP-2 dose/loading method |
|---|---|---|---|---|---|
| In vivo study | |||||
| Ike 199814 | Human tooth root | Normal, athymic mice/hindquarter muscles | Dentin block (1.0–2.0 mm3, 0.5 g) | 0.6 N HCl (PDM) | 1, 2, and 5 μg rhBMP-2/70 mg DDM: NA (Genetic Institute, Boston, MA) |
| Miyaji 200216 | Rat tooth root | Rats/palatal connective tissue | Dentin block (1 × 1 × 0.3 mm) | 24% EDTA (NA) | 50 and 100 μg/mL rhBMP-2: soaking (Yamanouchi Pharmaceutical, Japan) |
| Murata 201217 | Human DDM | Rats/subcutaneous pocket back | Powder (0.4–0.8 mm) | 0.6 N HCl (CDM) | 5.0 μg BMP-2/70 mg DDM: soaking (Yamanouchi Pharmaceutical, Japan) |
| Um 201627 | Rabbit DDM | Rabbits/calvarium | Powder (300–800 μm) | 0.6 N HCl (PDM) | 50 μg rhBMP-2/300 mg DDM: freeze-drying (Cowelmedi, Busan, Korea) |
| Um 201828 | Rabbit DDM | Mice/thigh muscle | Powder (300–800 μm) | 0.6 N HCl (PDM) | 50 μg rhBMP-2/300 mg DDM: freeze-drying (Cowelmedi, Busan, Korea) |
| Rabbit DDM | Rabbits/calvarium | Powder (300–800 μm) | 0.6 N HCl (PDM) | 50 μg rhBMP-2/300 mg DDM: freeze-drying (Cowelmedi, Busan, Korea) | |
| Clinical Study | |||||
| Um 201729 | Human DDM | Humans/alveolar bone | Powder (300–800 μm) | 0.6 N HCl (PDM) | 0.2 mg/mL rhBMP-2: freeze-drying, (Cowelmedi, Busan, Korea) |
| Jung 201830 | Human DDM | Humans/alveolar bone | Powder (300–800 μm) | 0.6 N HCl (PDM) | 0.2 mg/mL rhBMP-2: freeze-drying (Cowelmedi, Busan, Korea) |
| Um 201931 | Human DDM | Humans/alveolar bone | Powder (300–800 μm) | 0.6 N HCl (PDM) | 0.2 mg/mL rhBMP-2: freeze-drying (Cowelmedi, Busan, Korea) |
CDM, completely demineralized dentin matrix; DDM, demineralized dentin matrix; DDM/rhBMP-2, DDM loaded with rhBMP-2; EDTA, ethylenediaminetetraacetic acid; PDM, partially demineralized dentin matrix; NA, not available; rhBMP-2, recombinant human bone morphogenetic protein.